Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | PTGES | O14684 | 1/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.55 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6452235 | 0.89 | PTGDR2 (0.67) | FOLH1POLBKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL30591972 | 0.89 | PTGDR2 (0.67) | FOLH1POLBKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL4723723 | 0.89 | LRRK2 (0.58) | FOLH1POLBKDM4EALDH1A1LRRK2 | |
| SCHEMBL16898127 | 0.89 | FOLH1 (0.58) | FOLH1POLBKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL9876914 | 0.88 | LRRK2 (0.59) | FOLH1POLBKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL552025 | 0.88 | LRRK2 (0.57) | FOLH1POLBKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL5431545 | 0.87 | LRRK2 (0.63) | FOLH1POLBKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL28260622 | 0.87 | LRRK2 (0.59) | FOLH1POLBKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL1647819 | 0.86 | LRRK2 (0.60) | FOLH1L3MBTL1LRRK2LMNAPTGER1 | |
| SCHEMBL1647846 | 0.86 | CCR5 (0.62) | FOLH1LRRK2PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3867249-B1 | (ISOPROPYL-TRIAZOLYL)PYRIDINYL-SUBSTITUTED BENZOTHIAZINONE DERIVATIVES AS ASK1 INHIBTORS FOR THE TREATMENT OF METABOLIC DISORDERS | HK INNO N CORP (KR) | 2026-03-04 | — | — | EP | disclosed |
| US-12565491-B2 | (Isopropyl-triazolyl)pyridinyl-substituted benzooxazinone or benzothiazinone derivatives and use thereof | HK INNO.N CORPORATION (KR) | 2026-03-03 | — | — | US | disclosed |
| CN-116751200-A | Tricyclic compounds containing substituted pyridones and methods of using the same | 爱彼特生物制药公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-112812077-B | Benzamide compound, preparation method thereof, pharmaceutical composition and application | 中国科学院上海药物研究所 | 2023-08-22 | — | — | CN | disclosed |
| CN-110114071-B | Tricyclic compounds containing substituted pyridones and methods of using the same | 爱彼特生物制药公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20220033390-A1 | Novel (isopropyl-triazolyl)pyridinyl-substituted benzooxazinone or benzothiazinone derivatives and use thereof | HK INNO.N CORPORATION (KR) | 2022-02-03 | — | — | US | disclosed |
| CN-112839943-A | Novel (isopropyl-triazolyl) pyridyl substituted benzoxazinone or benzothiazinone derivatives and uses thereof | 怡诺安有限公司 | 2021-05-25 | — | — | CN | disclosed |
| CN-112812077-A | Benzamide compound and preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2021-05-18 | — | — | CN | disclosed |
| US-9914719-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9730912-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2017-08-15 | — | — | US | disclosed |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | ASTEX THERAPEUTICS, LTD. (GB) | 2007-11-08 | — | — | US | disclosed |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | US | disclosed |
| WO-2006114274-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
| WO-2005118613-A2 | ANTIBACTERIAL AMIDE MACROCYCLES | AICURIS GMBH & CO.KG (DE) | 2005-12-15 | — | — | WO | disclosed |
| EP-0752421-B1 | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists | ASTRAZENECA AB (SE) | 2005-10-12 | — | — | EP | disclosed |
| US-6787562-B2 | ANALGESICS; OSTEOPOROSIS | ZENECA LTD. (GB) | 2004-09-07 | — | — | US | disclosed |
| US-20030139418-A1 | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists | SYNGENTA LIMITED (GB) | 2003-07-24 | — | — | US | disclosed |
| US-6057345-A | ANTAGONISTS OF THE PAIN ENHANCING EFFECTS OF E-TYPE PROSTAGLANDINS; USED IN PAIN RELIEF | ZENECA LIMITED (GB) | 2000-05-02 | — | — | US | disclosed |
| US-5834468-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, ANALGESICS TREATING RHEUMATIC DISEASE, BONE DISORDER, INJURIES | ZENECA LIMITED (GB) | 1998-11-10 | — | — | US | disclosed |
| EP-0752421-A1 | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists | ZENECA LIMITED (GB) | 1997-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565491-B2 | (Isopropyl-triazolyl)pyridinyl-substituted benzooxazinone or benzothiazinone derivatives and use thereof | IRAK1, PEAK1, IRAK4 | FOLH1 3991/4885POLB 3197/4885KDM4E 2521/4885 |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | HSP90AB2P, HSP90AA1, HSP90AB1 | FOLH1 4191/4885POLB 1608/4885KDM4E 3534/4885 |
| US-20220033390-A1 | Novel (isopropyl-triazolyl)pyridinyl-substituted benzooxazinone or benzothiazinone derivatives and use thereof | TBK1, IRAK1, IRF3 | FOLH1 4558/4885POLB 3615/4885KDM4E 2813/4885 |
| US-20070259871-A1 | Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90 | HSP90AB1, HSP90AB2P, HSP90AA1 | FOLH1 4751/4885POLB 2452/4885KDM4E 3464/4885 |
| US-20030139418-A1 | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists | PTGER1, PTGDR, PTGER2 | FOLH1 3258/4885POLB 2940/4885KDM4E 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.